Since SGLT2 is upregulated in the kidneys of humans (and rodents) with diabetes [11] and at the same time accounts for virtually all of the glucose reabsorption in the kidney, it is well-established that pharmacological inhibition of renal SGLT2 results in glucosuria and reduced serum glucose levels. Here, SLC5A2 is linked to Glycosuria.